Skinfluenced - The Skin Podcast

Skinfluenced - The Skin Podcast
  • 5.0 (1)
  • MEDICINE
  • UPDATED WEEKLY

🧴 Harnessing the power of technology, Skinfluenced: The Skin Podcast keeps you plugged into the fast-moving worlds of dermatology, wellness, and aesthetics. From the latest journal articles and groundbreaking studies, to new FDA approvals, new product launches, and clinical insights—this podcast is your go-to source for evidence-based updates that matter. Whether you're a seasoned provider or just dipping your toe in the sand, you'll stay one step ahead of the trends, the science, and your skin. Disclaimer: All content is for educational purposes only and does not constitute medical advice.

  1. Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™

    11/11/2025

    Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode. Episode 15 Drop: Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™ In this episode of Skinfluenced: The Skin Podcast, we explore a groundbreaking advancement in the management of moderate-to-severe atopic dermatitis (AD). Castle Biosciences’ new AdvanceAD-Tx™ test, launched THIS MONTH, introduces precision medicine to dermatology with a 487-gene expression profile (GEP) that decodes each patient’s unique immune biology. By classifying results into different profile groups, clinicians can now identify which patients are more likely to respond to specific systemic therapies—before treatment even begins. We're breaking down: The IDENTITY study which showed how patients can now get EASI-90 nearly 4X fasterHow this innovation could transform treatment selection, improve patient outcomes, and redefine the role of molecular testing in dermatology.⚠️ Educational purposes only. Not medical advice. Link to Source(s): Castle Biosciences, Inc. Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis. Accessed November 11, 2025. https://ir.castlebiosciences.com/news/news-details/2025/Castle-Biosciences-Launches-AdvanceAD-Tx-to-Help-Guide-Systemic-Treatment-Decision-Making-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis/default.aspx Castle Biosciences, Inc. Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis. News Release. November 3, 2025. Chiesa Fuxench, Zelma C., et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. Journal of Investigative Dermatology. 2019; 139: 583–590. Silverberg, Jonathan I., et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Annals of Allergy, Asthma & Immunology. 2018; 121(3): 340-347. Silverberg, Jonathan I., et al. The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective, multi-center trial. Castle Biosciences AdvanceAD-Tx™ Launch Slide Deck. November 2025. The Derm Digest. Castle Biosciences Rolls Out AdvanceAD-Tx. Accessed November 11, 2025. https://thedermdigest.com/castle-biosciences-rolls-out-advancead-tx/?utm_source=Klaviyo&utm_medium=campaign&_kx=LStbfMDiK_dFORiyt1p_kkItQ6IXDv9wQWWp60o95yV8qS2-9Wbebg-OUZpTxSvC.TYhhHR

    14 min
  2. Press Release: Libtayo (Cemiplimab) Approved as First Adjuvant Immunotherapy for High-Risk cSCC

    10/23/2025

    Press Release: Libtayo (Cemiplimab) Approved as First Adjuvant Immunotherapy for High-Risk cSCC

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode. In this episode of Skinfluenced: The Skin Podcast, we break down the FDA’s recent approval of Libtayo® (Cemiplimab-rwlc) as the first and only adjuvant immunotherapy for patients with high-risk cutaneous squamous cell carcinoma (cSCC) following surgery and radiation. Join us as we discuss:🧬 The pivotal trial showing improved disease-free survival in high-risk cSCC💉 The evolving role of PD-1 blockade in post-surgical skin cancer management🧠 How this approval changes the treatment landscape for patients at risk of recurrence This landmark decision represents a major step forward in skin cancer care—bringing immunotherapy into the adjuvant setting and offering new hope for patients facing aggressive or recurrent cSCC. Link to Source(s): American Association for Cancer Research. Immunotherapy Approved for Preventing Recurrence of Certain Skin Cancers. Accessed October 22, 2025. https://tinyurl.com/ywpynwfn American Journal of Managed Care. FDA Approves Cemiplimab as First & Only Adjuvant Immunotherapy for High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/5b4s6jb7 Dermatology Advisor. FDA Approves Libtayo for Adjuvant Treatment of High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/58h5cckn Derm Digest. FDA Approves Cemiplimab to Treat cSCC With High Risk of Recurrence After Surgery and Radiation. Accessed October 22, 2025. https://tinyurl.com/2s9jjc53 Journal of Clinical Oncology. Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival in Patients With High-Risk Cutaneous Squamous Cell Carcinoma. Published 2025; 43(16_suppl):6000. Accessed October 22, 2025. https://tinyurl.com/27ekuzch New England Journal of Medicine. Adjuvant Cemiplimab for Cutaneous Squamous-Cell Carcinoma. Published 2025. Accessed October 22, 2025. https://tinyurl.com/4rynuvky OncLive. Dr. Patel on the FDA Approval of Adjuvant Cemiplimab for High-Risk Cutaneous Squamous Cell Carcinoma. Accessed October 22, 2025. https://tinyurl.com/4kvzbv8z Oncology Nursing Society. FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of High-Risk Cutaneous Squamous Cell Carcinoma. Published October 2025. Accessed October 22, 2025. https://tinyurl.com/4ne9rsv3 Regeneron Pharmaceuticals. Adjuvant Libtayo (cemiplimab) Significantly Improves Disease-Free Survival in Phase 3 Trial. Accessed October 22, 2025. https://tinyurl.com/3a9m5u6c Regeneron Pharmaceuticals. FDA Approves Libtayo (cemiplimab-rwlc) in the U.S. as the First and Only Adjuvant Immunotherapy for High-Risk cSCC. Accessed October 22, 2025. https://tinyurl.com/2hfs59k2 Regeneron Pharmaceuticals. Libtayo (cemiplimab) Phase 3 Data: Adjuvant Treatment Post-Surgery and Radiation. Accessed October 22, 2025. https://tinyurl.com/yx5xkzcr Regeneron Pharmaceuticals. Libtayo Full Prescribing Information. Accessed October 22, 2025. https://tinyurl.com/86w7ydjn Regeneron Pharmaceuticals. Libtayo Medication Guide. Accessed October 22, 2025. https://tinyurl.com/432jx77u ScienceDirect. Induction of Natural Cytotoxicity by Interferon: Studies on the Mechanism of Action. Trends in Biochemical Sciences. Published 1985. Accessed October 22, 2025. https://tinyurl.com/589swev2 #SCC #skincancer #skincancertreatment #Dermatology #SkinHealth #NewTreatments #FDAApproved #Therapies #ClinicalGuidelines #FDAApproval #SkinScience #EvidenceBasedMedicine #SCCManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

    15 min
  3. Press Release: Zoryve (roflumilast) 0.05% Cream Approved for Atopic Dermatitis in Ages 2-5

    10/08/2025

    Press Release: Zoryve (roflumilast) 0.05% Cream Approved for Atopic Dermatitis in Ages 2-5

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode. In this episode of Skinfluenced: The Skin Podcast, we break down the FDA’s latest approval of ZORYVE® (roflumilast) Cream 0.05%, marking a new topical treatment option for young children living with atopic dermatitis. Join us as we discuss:🌿 Clinical trial data showing safety and efficacy in patients aged 2–5 years💊 How PDE-4 inhibition with roflumilast differs from current treatment options🧴 What this means for real-world management of pediatric eczema This exciting update highlights continued innovation in pediatric dermatology and expands therapeutic options for our youngest patients. Link to Source(s): Arcutis. FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.05 for the Treatment of Atopic Dermatitis in Children Ages 2 to 5. Published October 6, 2025. Accessed October 8, 2025. https://www.arcutis.com/fda-approves-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-atopic-dermatitis-in-children-ages-2-to-5/ Arcutis Biotherapeutics. FDA Approves Arcutis’ ZORYVE (roflumilast) Cream 0.05 Treatment. Published October 6, 2025. Accessed October 8, 2025. https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-005-treatment HCPLive. FDA Approves Roflumilast (Zoryve) Cream 0.05 for Atopic Dermatitis in Children Aged 2-5 Years. Published October 6, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/fda-approves-roflumilast-zoryve-cream-0-05-for-atopic-dermatitis-in-children-aged-2-5-years HCPLive. Roflumilast Cream 0.05% Effective for Atopic Dermatitis in Patients Aged 2-5 Years. Published February 22, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/roflumilast-cream-0-05-effective-atopic-dermatitis-patients-aged-2-5-years HCPLive. Significance of Roflumilast Approval in Atopic Dermatitis Children — Lawrence Eichenfield, MD. Published October 8, 2025. Accessed October 8, 2025. https://www.hcplive.com/view/significance-roflumilast-approval-atopic-dermatitis-children-lawrence-eichenfield-md HMP Global Learning Network / The Derm. FDA Alerts: FDA Approves Roflumilast Cream 0.05 Treatment for Atopic Dermatitis in Children. Published October 6, 2025. Accessed October 8, 2025. https://www.hmpgloballearningnetwork.com/site/thederm/fda-alerts/fda-approves-roflumilast-cream-005-treatment-atopic-dermatitis-children The Derm Digest. U.S. FDA Approves Roflumilast Cream 0.05 for AD in Kids Aged 2 to 5. Published October 6, 2025. Accessed October 8, 2025. https://thedermdigest.com/u-s-fda-approves-roflumilast-cream-0-05-for-ad-in-kids-aged-2-to-5 Zoryve HCP. [Homepage]. Accessed October 8, 2025. https://www.zoryvehcp.com/ #AD #atopicdermatitis #Dermatology #SkinHealth #NewTreatments #FDAApproved #topicalTherapies #ClinicalGuidelines #FDAApproval #UTDDermatology #SkinScience #EvidenceBasedMedicine #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast

    15 min
  4. Press Release: FDA Approves Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria

    10/02/2025

    Press Release: FDA Approves Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today’s episode. In this episode of Skinfluenced: The Skin Podcast, we review the FDA’s September 30, 2025 approval of remibrutinib (Rhapsido, Novartis), the first oral BTK inhibitor indicated for chronic spontaneous urticaria (CSU). We’ll walk through the press releases, clinical trial data, and recent publications highlighting its efficacy, safety, and potential impact on treatment pathways for CSU. Link to Source(s): The American Journal of Managed Care (AJMC). FDA Approves Remibrutinib for Chronic Spontaneous Urticaria. Published September 30, 2025. Accessed October 1, 2025. https://www.ajmc.com/view/fda-approves-remibrutinib-for-chronic-spontaneous-urticaria BioSpace. Novartis Secures First FDA Approval of Oral BTK Inhibitor for Chronic Hives. Published September 30, 2025. Accessed October 1, 2025. https://www.biospace.com/fda/novartis-secures-first-fda-approval-of-oral-btk-inhibitor-for-chronic-hives ClinicalTrials.gov. A Study to Assess the Efficacy and Safety of Remibrutinib in Participants With Chronic Spontaneous Urticaria (NCT05030311). Updated 2025. Accessed October 1, 2025. https://clinicaltrials.gov/study/NCT05030311 ClinicalTrials.gov. A Study of Remibrutinib in Chronic Spontaneous Urticaria (NCT05032157). Updated 2025. Accessed October 1, 2025. https://clinicaltrials.gov/study/NCT05032157 Novartis. Novartis Receives FDA Approval for Rhapsido (Remibrutinib), the Only Oral Targeted BTKi Treatment for Chronic Spontaneous Urticaria (CSU). Published September 30, 2025. Accessed October 1, 2025. https://www.novartis.com/us-en/news/media-releases/novartis-receives-fda-approval-rhapsido-remibrutinib-only-oral-targeted-btki-treatment-chronic-spontaneous-urticaria-csu Practical Dermatology. FDA Approves Remibrutinib for Adults With CSU. Published September 30, 2025. Accessed October 1, 2025. https://practicaldermatology.com/news/fda-approves-remibrutinib-for-adults-with-csu/2483590/ Reuters. US FDA Approves Novartis Drug for Skin Disease. Published September 30, 2025. Accessed October 1, 2025. https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-novartis-drug-skin-disease-2025-09-30/ ScienceDirect. Remibrutinib in Chronic Spontaneous Urticaria: Results From Clinical Trials. Published 2022. Accessed October 1, 2025. https://www.sciencedirect.com/science/article/pii/S0091674922011812 The Derm Digest. Breaking News: The U.S. FDA Approves Remibrutinib (Rhapsido, Novartis) for CSU. Published September 30, 2025. Accessed October 1, 2025. https://thedermdigest.com/breaking-news-the-u-s-fda-approves-remibrutinib-rhapsido-novartis-for-csu/?utm_source=Klaviyo&utm_medium=campaign&_kx=LStbfMDiK_dFORiyt1p_kkItQ6IXDv9wQWWp60o95yV8qS2-9Wbebg-OUZpTxSvC.TYhhHR Taylor & Francis Online. Remibrutinib for Chronic Spontaneous Urticaria: Clinical Impact and Future Directions. Published 2025. Accessed October 1, 2025. https://www.tandfonline.com/doi/abs/10.1080/1750743X.2025.2510892

    14 min
  5. Press Release: Opzelura (ruxolitinib) 2% Cream Approved for Atopic Dermatitis in Ages 2 and Up

    09/21/2025

    Press Release: Opzelura (ruxolitinib) 2% Cream Approved for Atopic Dermatitis in Ages 2 and Up

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode. In this episode of Skinfluenced: The Skin Podcast, we review the brand new FDA approval of Opzelura® (ruxolitinib) cream 1.5% for children ages 2 and up with atopic dermatitis. This marks a major step forward in pediatric dermatology, offering the first topical JAK inhibitor option for younger patients with mild-to-moderate AD who need more than topical steroids or topical calcineurin inhibitors. We’ll discuss the clinical trial data from the TRuE-AD program, safety considerations, and where ruxolitinib cream may fit into the evolving treatment landscape for pediatric eczema. Tune in to learn what this means for providers, patients, and families navigating chronic AD care. #AtopicDermatitis #Eczema  #PediatricDermatology #Opzelura #Ruxolitinib #JAKInhibitor #Dermatology #SkinHealth #NewTreatments #FDAApproved #TopicalTherapies #ClinicalGuidelines #FDAApproval #EczemaTreatment #ADUpdate #SkinScience #EvidenceBasedMedicine #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast Link to Source(s): Business Wire. Incyte Announces U.S. FDA Approval of Opzelura (Ruxolitinib) Cream, a Topical JAK Inhibitor, for Treatment of Atopic Dermatitis (AD). Published September 21, 2021. Accessed September 20, 2025. ⁠https://www.businesswire.com/news/home/20210921006072/en/Incyte-Announces-U.S.-FDA-Approval-of-Opzelura-ruxolitinib-Cream-a-Topical-JAK-Inhibitor-for-the-Treatment-of-Atopic-Dermatitis-AD⁠ Contemporary Pediatrics. FDA Approves Ruxolitinib for Pediatric Atopic Dermatitis. Published July 29, 2025. Accessed September 20, 2025. ⁠https://www.contemporarypediatrics.com/view/fda-approves-ruxolitinib-for-pediatric-atopic-dermatitis⁠ Incyte. Incyte Announces FDA Approval of Opzelura (Ruxolitinib) Cream for Treatment of Vitiligo in Nonsegmental Patients 12 Years and Older. Published July 18, 2022. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/23156/pdf⁠ Incyte. Incyte Announces Positive Topline Results From Pivotal Phase 3 TRuE-AD Clinical Trial Program Evaluating Ruxolitinib Cream for Atopic Dermatitis. Published December 15, 2019. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/23376/pdf⁠ Incyte. Incyte Announces FDA Approval of Opzelura (Ruxolitinib) Cream for Treatment of Atopic Dermatitis in Pediatric Patients Ages ≥2 Years. Published July 29, 2025. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/25636/pdf⁠ Incyte. Incyte Announces FDA Approval of Opzelura (Ruxolitinib) Cream for Treatment of Nonsegmental Vitiligo in Patients 12 Years and Older. Published July 18, 2022. Accessed September 20, 2025. ⁠https://investor.incyte.com/node/25226/pdf⁠ Pharmacy Times. FDA Approves 1.5% Ruxolitinib Cream for Pediatric Atopic Dermatitis. Published July 29, 2025. Accessed September 20, 2025. ⁠https://www.pharmacytimes.com/view/fda-approves-1-5-ruxolitinib-cream-for-pediatric-atopic-dermatitis⁠ The American Journal of Managed Care (AJMC). FDA Approves Ruxolitinib Cream for Patients as Young as 2 Years With Atopic Dermatitis. Published July 29, 2025. Accessed September 20, 2025. ⁠https://www.ajmc.com/view/fda-approves-ruxolitinib-cream-for-patients-as-young-as-2-years-with-atopic-dermatitis⁠

    15 min
  6. 2025 Updated Guidelines of Care for the Management of Atopic Dermatitis in Adults

    09/15/2025

    2025 Updated Guidelines of Care for the Management of Atopic Dermatitis in Adults

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode. In this episode of Skinfluenced: The Skin Podcast, we’re breaking down the American Academy of Dermatology’s June 2025 focused update on the management of Atopic Dermatitis (AD) in adults. We’ll highlight how to integrate the latest high-quality evidence into practice, including new FDA-approved therapies that are reshaping the treatment landscape. From tapinarof and roflumilast creams, to biologics like lebrikizumab and nemolizumab, we review the data behind their efficacy and safety, drawn from multiple randomized controlled trials. You’ll also learn how these treatments fit within current regimens—whether used alone or in combination—so you can deliver the most accurate, evidence-based care for your AD patients.#AtopicDermatitis #Eczema #ADGuidelines #AADGuidelines #Dermatology #SkinHealth #NewTreatments #FDAApproved #TopicalTherapies #SystemicTherapies #Lebrikizumab #Nemolizumab #Tapinarof #Roflumilast #Biologics #ClinicalGuidelines #EvidenceBasedMedicine #AADUpdate2025 #AdultAD #ADManagement #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast Link to Source(s): Focused Update: Guidelines of Care for the Management of Atopic Dermatitis in Adults. Davis, Dawn M.R. et al. Journal of the American Academy of Dermatology, Volume 93, Issue 3, 745.e1 - 745.e7 https://www.jaad.org/article/S0190-9622(25)02125-5/fulltext

    17 min
  7. Just Released! Is PDGF Safe?

    09/09/2025

    Just Released! Is PDGF Safe?

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode. In this episode of Skinfluenced: The Skin Podcast, we have a brand new article to report on. Just a few days ago, a review of the safety of Platelet-Derived Growth Factor (PDGF) was released. Tune in to learn all about this topic of immense interest recently, as well as it’s importance in aesthetic and regenerative medicine. This white paper highlights over 25 years of extensive safety research, discussing the rhPDGF-bb safety profile and track record of use. We'll specifically discuss the findings related to cancer, including the FDA black box warning! Tune in to understand the compelling evidence regarding the true safety of this powerful regenerative protein. #PDGF #RegenerativeMedicine #GrowthFactorTherapy #AntiAging #SkinRejuvenation #CollagenBoost #Microneedling #HairRegeneration #CosmeticInnovation #Ariessence #HealingFaster #DermUpdate #SkinScience #Dermatology #DermatologyProvider #Dermatologist #CosmeticDermatology #Aesthetics #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast #DermatologyPodcast Link to Source(s): Hee CK, Slade HB, Lynch SE. A Review of the Safety of Exogenously Applied Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Medical and Cosmetic Applications. Lynch Regenerative Medicine, LLC; 2025. RPT-001. https://www.lynchregen.com/wp-content/uploads/2025/09/RPT-001v1.0-A-Review-of-the-Safety-of-Exogenously-Applied-rhPDGF-vFinal.pdf

    19 min
  8. Press Release: Wegovy (Semaglutide) now approved for MASH

    08/31/2025

    Press Release: Wegovy (Semaglutide) now approved for MASH

    Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode. In this episode of Skinfluenced: The Skin Podcast, we take a break from only skin diseases, and delve into our wellness side to take a look into some ground breaking research shaping the understanding and treatment of the newest GLP-1 indication: metabolic dysfunction–associated steatohepatitis (MASH). Join us as we dive into the groundbreaking developments surrounding semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, and its expanding therapeutic potential from upcoming FDA approvals to emerging pharmacologic strategies, this episode breaks down what these findings mean for providers, patients, and the future of disease management.#Semaglutide #MASH #LiverDisease #GLP1agonist #Wegovy #LiverFibrosis #Steatohepatitis #MetabolicHealth #Obesity #Type2Diabetes #WeightLoss #Cardiometabolic #ClinicalTrials #FDAApproval #ESSENCEtrial #HeartFailure #HFpEF #ChronicKidneyDisease #NeurodegenerativeDiseases #AlzheimersDisease #ParkinsonsDisease #MASLD #NAFLD #PhysicianAssistant #PhysicianAssociate #NursePractitioner #SkinfluencedPodcast  Link to Source(s): FDA (2024): FDA Approves Treatment for Serious Liver Disease Known as MASHhttps://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash Journal of Hepatology (2020): A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statementhttps://www.sciencedirect.com/science/article/abs/pii/S0168827820302014 PubMed (2022): Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative Diseases: A Narrative Reviewhttps://pubmed.ncbi.nlm.nih.gov/35650449/ PubMed (2023): Efficacy and Safety of Semaglutide in Non-Alcoholic Fatty Liver Diseasehttps://pubmed.ncbi.nlm.nih.gov/37899788/ PubMed (2024): Semaglutide Versus Placebo in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pooled Analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM Randomised Trialshttps://pubmed.ncbi.nlm.nih.gov/39222642/ PubMed (2025): Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitishttps://pubmed.ncbi.nlm.nih.gov/40004240/ The New England Journal of Medicine (2023): Semaglutide and Cardiovascular Outcomes in Obesity without Diabeteshttps://www.nejm.org/doi/full/10.1056/NEJMoa2307563 The New England Journal of Medicine (2025): Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitishttps://scholarindexing.com/uploads/files/8pu3_1ome6lcxkb.pdf

    12 min
See All (15)

About

🧴 Harnessing the power of technology, Skinfluenced: The Skin Podcast keeps you plugged into the fast-moving worlds of dermatology, wellness, and aesthetics. From the latest journal articles and groundbreaking studies, to new FDA approvals, new product launches, and clinical insights—this podcast is your go-to source for evidence-based updates that matter. Whether you're a seasoned provider or just dipping your toe in the sand, you'll stay one step ahead of the trends, the science, and your skin. Disclaimer: All content is for educational purposes only and does not constitute medical advice.

Information

  • Creator
    Skinfluenced - The Skin Podcast
  • Years Active
    2K
  • Episodes
    15
  • Rating
    Clean
  • Copyright
    © Skinfluenced - The Skin Podcast
  • Show Website
    Skinfluenced - The Skin Podcast